Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07105098 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Name: NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia — clinical trial record (NCT07105098)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorNeurocrine Biosciences

Started2025-08-11

View on ClinicalTrials.gov ↗

Amendment history

2026-09-26

Trial sites expanded: 15 → 20 locations

2026-05-13

Study Status, Contacts/Locations v3

Trial sites expanded: 11 → 15 locations

2026-04-10

Study Status, Contacts/Locations v2

Study sites5→11

2025-09-19

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-08→confirmed 2025-08-11

Study sites0→5

2025-07-29

Original filing

Neurocrine Biosciences

25 trials monitored

See 1 trial at risk

Schizophrenia

675 trials monitored

See 32 trials at risk

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

Trial Details

NCT Number	NCT07105098
Lead Sponsor	Neurocrine Biosciences
Conditions	Schizophrenia
Enrollment	284 participants
Start Date	2025-08-11
Primary Completion	2027-11 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2026-09-25